…
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged data. In addition, it provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, the company offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Craneware is a UK-listed healthcare software company that provides revenue integrity, billing analytics and revenue cycle SaaS to hospitals and health systems, mainly in the United States. Long-term growth may be driven by complexity in hospital billing, adoption of automation and analytics, recurring subscription revenues and cross-selling, which could support predictable cash flow and scalable margins.
Principal risks include sensitivity to US reimbursement and regulatory changes, pressure on hospital budgets, competitive and execution risk as it expands, customer concentration and foreign exchange exposure; investors should monitor renewals and regulatory developments.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | 23.98M | 15.75M | 13.09M | 13.10M | 13.16M |
| Net income | 19.66M | 11.70M | 9.23M | 9.41M | 12.90M |
| Selling general administrative | - | - | 20.38M | 20.38M | 9.30M |
| Selling and marketing expenses | - | - | 15.27M | 15.27M | 6.62M |
| Gross profit | 179.27M | 162.20M | 148.44M | 142.37M | 70.20M |
| Reconciled depreciation | - | 33.38M | 32.16M | 29.40M | 5.24M |
| Ebit | 25.35M | 20.88M | 17.38M | 20.24M | 19.73M |
| Ebitda | 38.80M | 54.26M | 49.54M | 49.64M | 24.97M |
| Depreciation and amortization | 13.45M | 33.38M | 32.16M | 29.40M | 5.24M |
| Operating income | 25.25M | 19.73M | 19.23M | 18.13M | 13.24M |
| Other operating expenses | 180.41M | 169.53M | 156.85M | 145.11M | 55.80M |
| Interest expense | 1.27M | 5.13M | 6.36M | 5.03M | 0.08M |
| Tax provision | - | 4.04M | 3.85M | 3.69M | 0.26M |
| Interest income | - | 1.14M | 0.21M | 0.00M | 0.00M |
| Net interest income | - | -3.99M | -6.14M | -5.03M | -0.07M |
| Income tax expense | 4.32M | 4.04M | 3.85M | 3.69M | 0.26M |
| Total revenue | 205.66M | 189.27M | 174.02M | 165.54M | 75.58M |
| Total operating expenses | 154.02M | 142.46M | 131.28M | 121.93M | 50.43M |
| Cost of revenue | 26.38M | 27.07M | 25.58M | 23.18M | 5.37M |
| Total other income expense net | -1.27M | -3.99M | -6.65M | -7.14M | -6.56M |
| Net income from continuing ops | - | 11.70M | 9.23M | 9.41M | 12.90M |
| Net income applicable to common shares | - | - | 9.23M | 9.41M | 12.90M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 551.06M | 543.65M | 576.98M | 568.79M | 311.60M |
| Intangible assets | 185.73M | 202.23M | 216.56M | 230.69M | 31.92M |
| Other current assets | 8.36M | 4.14M | 41.25M | 41.25M | 19.43M |
| Total liab | 213.50M | 215.06M | 249.13M | 235.77M | 51.32M |
| Total stockholder equity | 337.56M | 328.59M | 327.84M | 333.02M | 260.28M |
| Deferred long term liab | - | - | - | 0.03M | 1.69M |
| Other current liab | 148.41M | 131.81M | 0.14M | 0.02M | 0.43M |
| Common stock | 0.66M | 0.66M | 0.66M | 0.66M | 0.62M |
| Capital stock | - | 0.66M | 0.66M | 0.66M | 0.62M |
| Retained earnings | 44.27M | 39.34M | 39.88M | 42.24M | 46.83M |
| Other liab | - | - | 44.45M | 48.17M | 0.76M |
| Good will | 235.24M | 235.24M | 235.24M | 237.65M | 11.19M |
| Other assets | - | - | 2.76M | 3.23M | 10.89M |
| Cash | 55.92M | 34.59M | 78.54M | 47.16M | 235.62M |
| Total current liabilities | 181.11M | 148.76M | 127.38M | 82.51M | 49.41M |
| Current deferred revenue | - | 16.86M | 113.85M | 58.70M | 32.19M |
| Net debt | -24.27M | 5.56M | 8.15M | 65.93M | -234.47M |
| Short term debt | 28.64M | 8.95M | 9.39M | 8.00M | 1.05M |
| Short long term debt | - | 8.00M | 8.00M | 8.00M | - |
| Short long term debt total | 31.65M | 40.15M | 86.69M | 113.08M | 1.15M |
| Other stockholder equity | 94.40M | 92.71M | -40.54M | -42.90M | -47.45M |
| Property plant equipment | - | - | 8.46M | 8.82M | 2.55M |
| Total current assets | 119.59M | 93.23M | 113.96M | 88.41M | 255.05M |
| Net tangible assets | - | - | -123.95M | -135.31M | 217.17M |
| Net receivables | 55.31M | 54.49M | 24.17M | 35.31M | 17.04M |
| Long term debt | - | 27.37M | 75.03M | 103.59M | - |
| Inventory | - | -7.79M | - | - | - |
| Accounts payable | 4.06M | 3.73M | 4.00M | 15.79M | 15.74M |
| Accumulated other comprehensive income | 198.23M | 195.88M | - | - | - |
| Common stock total equity | - | - | - | - | 0.62M |
| Non currrent assets other | 4.25M | 4.37M | -460.26M | 3.23M | -45.66M |
| Non current assets total | 431.47M | 450.43M | 463.01M | 480.39M | 56.55M |
| Capital lease obligations | - | 4.78M | 3.66M | 1.50M | 1.15M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | -15.81M | -15.34M | -307.32M | -10.32M |
| Change to liabilities | - | - | -5.46M | -13.50M | 4.20M |
| Total cashflows from investing activities | -13.98M | -15.81M | -15.34M | -307.32M | -10.32M |
| Net borrowings | - | -48.00M | -30.55M | 109.97M | -0.96M |
| Total cash from financing activities | -24.58M | -70.00M | -53.28M | 91.90M | 174.55M |
| Change to operating activities | - | - | 50.55M | 50.55M | 50.55M |
| Net income | 19.66M | 15.75M | 13.09M | 13.10M | 13.16M |
| Change in cash | 21.33M | -43.95M | 31.38M | -188.46M | 187.77M |
| Begin period cash flow | 34.59M | 78.54M | 47.16M | 235.62M | 47.85M |
| End period cash flow | 55.92M | 34.59M | 78.54M | 47.16M | 235.62M |
| Total cash from operating activities | 59.90M | 41.86M | 98.75M | 26.96M | 23.54M |
| Issuance of capital stock | - | 0.28M | -0.04M | 1.49M | 187.33M |
| Depreciation | 34.21M | 33.38M | 32.16M | 29.40M | 5.24M |
| Other cashflows from investing activities | -13.49M | -14.62M | 0.21M | 0.00M | 0.00M |
| Dividends paid | 13.27M | 12.80M | 12.12M | 12.98M | 9.70M |
| Change to account receivables | -7.07M | -21.18M | 1.12M | -3.20M | 2.03M |
| Sale purchase of stock | -0.10M | -3.35M | -3.81M | -1.73M | -0.42M |
| Other cashflows from financing activities | -2.35M | -6.13M | -9.31M | 116.09M | 184.25M |
| Change to netincome | - | - | 11.15M | 4.85M | -0.83M |
| Capital expenditures | 0.49M | 16.96M | 15.55M | 14.03M | 10.33M |
| Change in working capital | 0.97M | -4.01M | 46.20M | -16.70M | 6.22M |
| Stock based compensation | 5.70M | 4.49M | 2.99M | 2.12M | 2.14M |
| Other non cash items | -0.64M | -7.74M | 6.14M | 5.03M | 0.07M |
| Free cash flow | 59.41M | 24.91M | 83.20M | 12.93M | 13.21M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRW Craneware Plc |
2.00 0.18% |
1088.00 | 29.63 | 11.26 | 2.36 | 1.84 | 2.89 | 9.61 |
| OPT Optima Health plc |
- -% |
243.50 | 15.04 | 13.59 | 1.42 | 0.96 | 1.52 | 10.54 |
| DXRX Diaceutics PLC |
1.50 0.75% |
200.50 | - | 178.57 | 4.07 | 3.51 | 3.53 | 35.21 |
| KOO Kooth plc |
- -% |
189.50 | 16.06 | 11.38 | 0.64 | 1.42 | 0.35 | 2.52 |
| COG Cambridge Cognition Holdings Plc |
- -% |
28.00 | - | 12.84 | 2.01 | 7.68 | 2.10 | 100.23 |
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged data. In addition, it provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, the company offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
1 Tanfield, Edinburgh, United Kingdom, EH3 5DA
44 13 1550 3100
765
| Name | Title | Year Born |
|---|---|---|
| Mr. Keith Neilson | Co-Founder, CEO & Exec. Director | 1969 |
| Mr. Craig Thomas Preston ACA | CFO, Company Sec. & Exec. Director | 1971 |
| Ms. Isabel Urquhart | Chief People Officer & Director | 1968 |
| Mr. Abhilesh Gandhi | Group Chief Technology Officer | NA |
| Mr. Derek William Paterson | Chief Information Officer | 1968 |
| Mr. Eric Carter | Chief Legal Officer | NA |
| Mr. Mark Montgomery | Chief Marketing Officer | NA |
| Mr. Seth Droe | Chief Revenue Officer | NA |
| Ms. Karen Bowden RHIA | Exec. VP of Customer Management | NA |
| Ms. Lidia A. Rodriguez-Hupp | Chief Customer Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.